Adaptimmune Therapeutics (ADAP) 2024 Wells Fargo Healthcare Conference summary

Company overview and strategic direction

• Focused on engineered TCR therapies for solid tumors, aiming to transform cancer treatment by targeting intracellular antigens and delivering natural immune responses.

• Built fully integrated capabilities from research to commercialization, emphasizing manufacturing and CMC as key differentiators.

• Transitioned to a commercial-stage company with FDA approval of Tecelra, the first engineered cell therapy for a solid tumor.

• Targeting the sarcoma space, aiming to establish a franchise and own the cell therapy market for sarcomas.

Product launch and patient journey

• High anticipation for Tecelra among synovial sarcoma physicians and patients, with initial launch in 6–10 centers, expanding to 30.

• Expect first patient infusions in Q4, about three months post-approval, with regular updates on apheresis and treatment center onboarding.

• Patient journey includes parallel HLA and MAGE-A4 testing, insurance clearance, leukapheresis, 6–8 week manufacturing, and reinfusion.

• Sponsored testing enables broad patient access and supports a national referral network.

Market access and reimbursement

• List price for Tecelra set at $727,000, with positive payer feedback due to the rarity and unmet need in the patient population.

• Majority of eligible patients expected to have commercial insurance, with Medicare and Medicaid coverage to follow.

• Applying for NTAP payment to support Medicare reimbursement, expected next year.